NewsRx Logo Login/Signup
Home Newsletters Products Library About Us Contact -- Search NewsRx

NewsRx | Free Trials
Advertisement
VerticalNews | Global Warming
NewsRx | Free Newsletters
 
----------
------------
NewsRx on Facebook
-----
NewsRx Passes
Press Release Submissions
PR Login
-----
2008 Award Logo
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
-----
Google 2009 PageRank: #2 Among Top Health News and Media Publications
Google 2009 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2009 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2009 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.

Security by Verisign

Search Results for Zidovudine


Filter Articles: Clinical News | Consumer News | Business News | All News | More Options

Results 1 - 20      Next >


Refine Search
Display Mode: Context | Summary
Data on clinical trial research detailed by P. Leger and co-authors
2009 SEP 28 ... patients initiating once-daily treatment with efavirenz plus twice-daily treatment with zidovudine and lamivudine. Plasma drug concentrations were determined at weeks 2 and 4. Drug doses ...
Subject: Clinical Trial Research
Price: $3.00
*
Data on HIV/AIDS discussed by C. Barau and colleagues
2009 OCT 5 ... At the time of surgery, the patient was on quadruple antiretroviral therapy (lamivudine, zidovudine, and amprenavir/ritonavir)." "Immunosuppression was initiated with ...
Subject: HIV/AIDS
Price: $3.00
*
FDA Advisory Committee Recommends Approval of Pfizer's Selzentry for Use in Patients Starting HIV Therapy for the First Time
2009 NOV 1 ... Results of MERIT at 48-weeks showed that Selzentry plus Combivir® (zidovudine/lamivudine) was as effective as Sustiva® (efavirenz) plus...
Subject: Pfizer Inc
Price: $3.00
*
New data from Brown University illuminate research in HIV/AIDS co-infection therapy
2009 SEP 28 ... inhibitors in TB/HIV-coinfected Ghanaian patients: UGT2B7*1c is associated with faster zidovudine clearance and glucuronidation.' "There are limited data on the pharmacokinetics of ...
Subject: HIV/AIDS Co-Infection Therapy
Price: $3.00
*
New transdermal delivery study findings have been reported from North-West University
2009 SEP 28 ... of novel methoxypoly (ethylene glycol) carbonate prodrugs of the antiretroviral drug zidovudine (azidothymidine, AZT) in an attempt to enhance the physicochemical properties for ...
Subject: Transdermal Delivery
Price: $3.00
*
Recent findings from Northwestern University highlight research in HIV/AIDS
2009 NOV 9 ... Three hundred seven of 338 (90.8%) patients had previously received stavudine and/or zidovudine + lamivudine + efavirenz or nevirapine; 41 of 338 (12.1%) had received tenofovir (TDF). ...
Subject: HIV/AIDS
Price: $3.00
*
Recent studies by V. Tozzi and co-authors add new data to HIV/AIDS findings
2009 OCT 12 ... nervous system penetration reference score (number of drugs in the combination among zidovudine, abacavir, stavudine, lamivudine, efavirenz, nevirapine, indinavir, and ...
Subject: HIV/AIDS
Price: $3.00
*
Reports from Kanazawa University describe recent advances in adenovirus
2009 NOV 2 ... flutamide, isoniazid, nifedipine, sulfamethoxazole, trazodone, troglitazone, and zidovudine demonstrated significant increases of SOD2- and CYP3A4-mediated cytotoxicity," wrote Y. ...
Subject: Adenovirus
Price: $3.00
*
Reports on HIV/AIDS findings from L. Calza and co-researchers provide new insights
2009 OCT 5 ... therapy (of at least 48-week duration), including one protease inhibitor and zidovudine or stavudine, with stable immunovirologic features, and having diagnosis of persisting ...
Subject: HIV/AIDS
Price: $3.00
*
Reports outline DNA research from Indiana University
2009 NOV 16 ... toxicity of the nucleoside analogue AZT (3'-azido-3'-deoxythymidine; known as zidovudine) is caused by inhibition of thymidine kinase 2 of the salvage pathway and subsequent TTP ...
Subject: DNA Research
Price: $3.00
*
Research data from A.S. Belanger and colleagues update understanding of enzyme research
2009 OCT 19 ... Drug Efavirenz by UGT2B7 and an in Vitro Investigation of Drug-Drug Interaction with Zidovudine. Drug Metabolism and Disposition, 2009;37(9):1793-1796). For additional ...
Subject: Enzyme Research
Price: $3.00
*
Research on HIV/AIDS described by scientists at GlaxoSmithKline
2009 SEP 21 ... study evaluating the efficacy and safety of once-daily coformulated abacavir/lamivudine/zidovudine plus tenofovir in ART-naive, HIV-infected subjects. We examined the patterns of ...
Subject: HIV/AIDS
View Free
Daily News
Article
Researchers from University of Rochester report details of new studies and findings in the area of myopathy
2009 NOV 23 ... dominate recent reports of all toxic myopathies. The peculiar mitochondrial pathology of zidovudine-induced mitochondrial DNA depletion, cytochrome oxidase depletion, and mitochondrial ...
Subject: Myopathy
Price: $3.00
*
Studies from J.L. Fang et al in the area of apoptosis described
2009 OCT 19 ... According to recent research from the United States, "Zidovudine (3'-azido-3'-deoxythymidine; AZT), which is currently used in the treatment of ...
Subject: Apoptosis
Price: $3.00
*
Studies from T. Puthanakit and co-researchers yield new data on HIV/AIDS in children
2009 NOV 1 ... or a low dose (70% of the standard dose) twice daily in combination with zidovudine and lamivudine. A 12 h pharmacokinetic study was done at 4-6 weeks after starting ...
Subject: HIV/AIDS
Price: $3.00
*
Study data from Imperial College, Faculty of Medicine update knowledge of HIV/AIDS risk factors
2009 NOV 1 ... data have been reported, an increased risk of pre-term delivery with HAART compared with zidovudine monotherapy remains a concern." Martin and colleagues published their ...
Subject: HIV/AIDS Risk Factors
Price: $3.00
*
Study results from N.A. Margot and colleagues in the area of HIV/AIDS published
2009 NOV 9 ... of emtricitabine + tenofovir DF + efavirenz (FTC + TDF + EFV) compared with lamivudine + zidovudine + efavirenz (3TC + ZDV + EFV) in antiretroviral therapy-naive HIV-1 infected subjects. ...
Subject: HIV/AIDS
Price: $3.00
*

Results 1 - 20      Next >




-----------------------
PR Login